Results 151 to 160 of about 2,201,777 (199)

ZDHHC11-mediated AXL palmitoylation promotes osimertinib resistance in non-small-cell lung cancer. [PDF]

Proc Natl Acad Sci U S A
Cui H, Cai X, Qian Q, Fan S, Li T, Wang T, Dai H, Song Y, Sun X, Cao P.   +9 more
europepmc   +1 more source

Abnormally Activated MNX1 Promotes Tumor Growth and Osimertinib Resistance and Predicts Survival in EGFR-Mutant Lung Adenocarcinoma. [PDF]

Drug Des Devel Ther
Gu W, Gan J, Liu P, Lai J, Liu C, Zhang G, Shi C, Jiang Q, Qiu F.   +8 more
europepmc   +1 more source

Taxanes Versus Pemetrexed After Osimertinib Resistance in EGFR-Mutated NSCLC: A Retrospective Cohort with Two-Model In Vitro Validation. [PDF]

Cancer Manag Res
Yang N, Wan N, Guo Y, Xiong L, Chen X, Du D, Xie B, Zhou J.   +7 more
europepmc   +1 more source

SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in <i>EGFR</i>-mutant lung cancer. [PDF]

Sci Signal
Daley BR, Theard PL, Hughes JM, Finniff BA, Hofmann MH, Kostyrko K, Schenk RL, Vieira HM, Askew JW, Lewis RE, Kortum RL.   +10 more
europepmc   +1 more source

USP28 Promotes Osimertinib Resistance in H1975 NSCLC Cells by Deubiquitinating and Stabilizing SIRT1. [PDF]

Kaohsiung J Med Sci
Fan HS, Li XM, Gu JQ, Wang HF, Zhang ZJ.
europepmc   +1 more source

Cancer-associated fibroblasts promote osimertinib resistance in non-small cell lung cancer cells via METTL1-mediated NET1 m⁷G modification. [PDF]

Cell Death Dis
Qian Y, Gong Z, Jia Y, Zhang Q, Cao L, Li B, Zhang J, Wang M, Wu X, Xu K.   +9 more
europepmc   +1 more source

Long-term survival following SCLC transformation after osimertinib resistance in <i>EGFR</i>-mutant NSCLC: Benefit from local surgical resection and osimertinib rechallenge. [PDF]

Genes Dis
Zhang Q.
europepmc   +1 more source

IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non-small cell lung cancer. [PDF]

Mol Cancer
Ibusuki R, Iwama E, Shimauchi A, Kawano H, Mizusaki S, Nakamura S, Miyazaki Y, Inutsuka Y, Hashisako M, Harada T, Tsuchiya-Kawano Y, Tsutsumi H, Nakanishi T, Nakagaki N, Koga Y, Kimura S, Mashimoto S, Shibahara D, Otsubo K, Yoneshima Y, Tanaka K, Oda Y, Okamoto I.   +22 more
europepmc   +1 more source

Identification of SUMOylation modifiers involved in lung adenocarcinoma progression and Osimertinib resistance by integrated bioinformatics analysis. [PDF]

Sci Rep
Yang X, Liu Y, Jiang W, Liu X, Zhang X, Liu H, Xing D, Wang K, Zheng X, Jiang W.   +9 more
europepmc   +1 more source

c-MET Inhibition Reverses the Osimertinib Resistance in Lung Circulating Tumor Cell Clusters and Suppresses Metastasis. [PDF]

Biol Proced Online
Zhang Z, Lu X, Tian J, Li J, Liu S, Liu J, Luo B, Yao J, Liu Y, Wang Y, Yao W, Yang Y, Shangguan W, Que Z.   +13 more
europepmc   +1 more source